Despite the use of more radical surgery and the advent of active chemotherapy, the long-term prognosis in epithelial ovarian cancer (EOC) is still largely determined by tumour characteristics rather than by the treatment administered. While many patients with early disease may remain diseasefree following primary surgery, the majority of patients present with advanced disease, which is not amenable to complete surgical extirpation. In these patients further treatment must realistically be regarded as palliative. Chemotherapy is now the standard treatment in such patients (Blackledge et al., 1987) and although response rates as high as 90% have been reported using cisplatinum containing regimens (Williams et al., 1985) , these results have not been translated into significant improvements in survival. Nevertheless some patients will derive considerable short-term benefit. Such active chemotherapy can be toxic so it is desirable to be able to select patients likely to benefit and likewise to use more appropriate therapy in poor-risk patients.
Currently therapeutic decisions are largely based on FIGO staging, residual disease status after primary surgery and performance score, which can be regarded as indirect manifestations of tumour biology (Redman et al., 1986) . Assessment of conventional tumour characteristics, such as histological type and grade are of value but are subjective and are confounded by tumour heterogenicity.
The advent of flow cytometry has facilitated objective assessment of tumour cell morphometry. These studies have largely evaluated ploidy, and S-phase fraction (Friedlander et al., 1984a,b; Blumenfeld et al., 1987; Rodenburg et al., 1987; Fowler et al., 1988 (McGuire & Dressler, 1985) . Aneuploid tumours tend to have a higher S-phase fraction when compared to diploid tumours (Kallioniemi et al., 1987) , but few data are available on P1 as a prognostic variable in ovarian cancer.
In addition to morphological studies it is also possible to quanitify indirectly tumour activity by the assay of products of cellular metabolism. Cyclic guanosine 3':5' monophosphate (cGMP) has been evaluated in this respect. Urinary cGMP levels correlate with tumour bulk (Turner et al., 1982) . In addition to this observation, Luesley et al. (1986) noted an independent effect of elevated urinary cGMP levels on survival in patients with residual epithelial ovarian cancer. Many workers have previously noted relationships between cGMP metabolism and cellular growth (Kupetz & Jeter, 1983; Seifert & Rudland, 1974; Weinstein et al., 1974; Zeilig & Golberg, 1977) . This relationship viewed alongside the clinical observation of a non-volume dependent effect on survival lead to the hypothesis of cGMP being a marker for tumour activity rather than volume. In order to test the hypothesis that elevated levels of cGMP do in fact represent increased tumour cell activity and to evaluate the independent prognostic value of cGMP, ploidy and S-phase fraction this study was performed.
Materials and methods

Patients
The study group comprised 40 patients with histologically proven EOC who had had postoperative, pretreatment urinary cGMP levels assayed and in whom there was archive histological material available to enable the cytometric studies to be performed. This cohort of patients had been recruited into an earlier study evaluating cGMP as a tumour marker in EOC (Luesley et al., 1986 All patients were staged according to the FIGO classification (Peterson et al., 1985) . The disease status at the end of primary surgery was recorded in detail for all patients. Histological material was centrally reviewed and classified using WHO criteria (Serov et al., 1973 (Luesley et al., 1986) . A cut-point of 90 nmol mmol ' creatinine was used, a level exceeded by 1 % of normal controls.
Flow cytometry Paraffin-embedded material was available on all patients. All tissue had been formalin fixed and processed using standard histological techniques. Thirty gsm sections were supplied from each block by the pathology department responsible for the original histopathological preparation and diagnosis. These sections were taken from blocks containing >70% tumour cells and an adjacent 5 gm haematoxylin and eosin stained section was also supplied from each block to ensure adequate tumour presence.
Single cell suspensions were prepared using the method of Hedley et al. (1983) , with minor modifications. Two 30 lm sections were dewaxed in xylene and rehydrated through graded alcohol (100%, 90%, 70%, 50%) into distilled water. The sections were treated with a 1% pepsin solution (pH = 1.5) for 30-60 min at 37°C with vortex agitation. Cell counts were then performed using a haemocytometer and provided more than 105 cells ml' were present, the suspension was centrifuged at 2,500 r.p.m. for 10 min. The resulting pellet was resuspended in 1 ml 10-2 M Tris (2-amino-2-(hydroxymethyl) propane 1 3,3-diol (tris)) (Analar BOH), pH 7.0, containing 5 ltM MgCl2 (BOH) as described by Deitch et al. (1982) . Specimens were filtered through 100 jtm pore size nylon gauze (cadisch) before storage at 4°C. Immediately preceding analysis specimens were stained using a modification of the method of Goh et al. (1986) . Briefly, 0.5 ml propidium iodide (propidium iodide-conc. I mg ml' in Tris buffer pH 7.0, sigma) with 0.5 ml ribonuclease type I AS (RNAse) (2 mg ml-' in Tris buffer pH 7.0, sigma) was added to remove double stranded RNA stained by the propidium iodide and incubated for 15 min at 37°C. Cell clumping and overestimation of the S-phase fraction was reduced by passing the suspension through a 25 gauge needle several times (Camplejohn et al., 1985) , prior to filtration through a 35 tim pore size nylon gauze. A record of each sample was made by placing a drop on a slide allowing it to air dry prior to staining by Papanicolaou's method.
Nuclear DNA content was measured using a Becton Dickenson FACS 440 cell sorter with an argon ion laser light source (laser excitation 200 mW at 488 nm, spectral physics). The instrument was aligned using chicken red blood cells (c RBC) and propidium iodide coated beads, before and after analysis of the samples. Thirty thousand nuclei were analysed at a rate of 700 per second, with low fluorescent particles gated out of the analysis.
Cell cycle analysis and calculation of the coefficient of variation (CV%) were performed using software supplied by Becton Dickinson. The CV% was calculated for each G, peak as a meaasure of the technique's ability to resolve two closely situated GI peaks (DI< 1.1). Histograms having a CV% > 8 were excluded from the analysis as being unsatisfactory and were not regarded as being indicative of aneuploidy. The DNA index (DI) was calculated as the ratio of multiple G, peaks to the G, diploid in channel numbers (DI 1.0 = single diploid GI). The proliferative index (PI) was calculated as the summation of all nuclei in the S and G2 phases of the histogram. Tumour cells sharing a common G, peak with normal cells were defined as diploid (DI = 1.0) but those possessing one or more extra peaks were defined an aneuploid (DI> 1.0). Aneuploidy was thus defined when tumours had obvious discernible separate GO/G, peaks with a DNA index greater than 1.0. Tumours possessing G2 peaks containing more than 15% of the total cells were graded as diploid with a high PI and were not considered aneuploid. Proliferative index was calculated from the summation of all nuclei in the S and G2 phases of the histogram and is defined in this study the the equation PI=S+ G2/G, + S + G2 x 100 In the case of aneuploid tumours or histograms shqwing two separate G, peaks, the cell kinetics data were determined only for the aneuploid subpopulations of the tumour.
Statistical methods
All patient data was stored using the facilities of the West Midlands Cancer Research Campaign Trials Unit. The statistical analyses were performed using the BMCP (Biomedical Programs, Los Angeles, California) statistical software (Dixon, 1988) . The differences in survival between groups tested using the log rank test (Peto et al., 1977) . A multivariate stepwise discriminatant analysis of outcome was performed using survival at 36 months as the end-point.
Results
In patients with evaluable disease (n = 25), there was a clinical response rate of 64% (16/25), eight of whom had a complete clinical response. Thirty-one patients have died and the median survival is 27 (95% confidence limits 20-34) months. The median time on-study is 46 months.
The median CV% was 6.3 (range 3.7-7.8; mean 6.01). Nine tumours were aneuploid. There was no significant association between ploidy and other conventional prognostic factors, including stage, bulk of residual disease, histological type and grade, although all the mucinous tumours were diploid (Table II) . There was a substantial negative correlation between aneuploidy and the amount of postoperative disease, although this failed to reach formal levels of statistical significance.
The distribution of PI appeared bimodal and a cut-point of 40% was used to categorise the data (Figure 1) . The relationship between PI and other prognostic variables is summaried in Table III . Overall the mean PI was 36% (range = 6-89). All the mucinous tumours had a PI of less Proliferative index (%) Figure 2 Association between proliferative index and cGMP levels.
( Table IV Tattersall (1987) reported that 62% of all malignant epithelial ovarian cancers were aneuploid, and this figure was probably higher in stage II and IV patients. The absence of a demonstrable relationship between tumour cell ploidy and grade of differentiation is also contrary to the findings of previous studies (Feichter et al., 1985) . The reason for these discrepancies is not clear and may be a function of the small size of the study group and/or our stringent definition of aneuploid histograms as described earlier. Tumour ploidy was not a prognostic factor as have been previously reported in two large studies (Hedley et al., 1985; Rodenberg et al., 1987) . However, these studies had a larger proportion of early stage (FIGO I/II) patients and it is clear that the prognostic significance of ploidy is reduced in more advanced tumours (Kallioniemi et al., 1988) ; indeeed in stage IV patients it ceases to have prognostic value (Tattersall, 1987) .
The significant association between PI and cGMP suggests that they may reflect a common parameter, namely that of tumour cell activity. On the basis of PI criteria, the study group be categorised into two sub-populations. PI was (Christov et al., 1987) , but the relationship of ploidy with cGMP was less marked. In this respect it must be remembered that as a marker of tumour cell activity, urinary cGMP levels is relatively non-specific as it is influenced by a number of factors, including tumour bulk (Luesley et al., 1986) . The observation that cGMP may have more prognostic weight than PI may be a function of this. The fact that 22% of the study group were classified as FIGO stage II would suggest that understaging was likely, and therefore might also apply to the assessment of post-operative disease.
In this respect cGMP levels may contribute additional value about post-operative status. These data indicate that increased tumour cell activity, reflected by elevated cGMP and PI values, has some adverse prognostic significance, but of less relevance than that of FIGO stage and postoperative tumour bulk. In clinical terms the additional information contributed by tumour cell activity would appear to have little current application in the management of advanced ovarian cancer. The conclusions drawn from this preliminary study, limited by the relatively small number of patients studied, need to be substantiated by further evaluation.
